NOVAFERON¡ªChronic Hepatitis B Clinical Trial Achieved Breakthrough
Full Title:Drug Innovation ProjectNOVAFERON in Chronic Hepatitis B Clinical ResearchCompletely Unblinding National Significant New Drug Innovation ProjectNOVAFERON in the treatment of Chronic Hepatitis B in Randomized, Double-Blind, Positive Control
Full Title:Drug Innovation ProjectNOVAFERON in Chronic Hepatitis B Clinical ResearchCompletely Unblinding National Significant New Drug Innovation ProjectNOVAFERON in the treatment of Chronic Hepatitis B in Randomized, Double-Blind, Positive Control
NOVAFERON for Treatment of Melanoma Clinical Research Launched
In August 3rd 2011, the start meeting for recombinant high efficient anti-tumor and anti-viral protein injection curing melanoma was held in Beijing Cancer Hospital. Professor Guo Jun, the leading person of melanoma research in China and the Director
In August 3rd 2011, the start meeting for recombinant high efficient anti-tumor and anti-viral protein injection curing melanoma was held in Beijing Cancer Hospital. Professor Guo Jun, the leading person of melanoma research in China and the Director
World Hepatitis Day ¨C July 28th
Approximately 1 in 12 persons worldwide, or some 500 million people, are living with chronic viral hepatitis. Viral hepatitis is among the top 10 infectious disease killers and the leading cause of liver cancer and cirrhosis. July 28th, 2011 is Worl
Approximately 1 in 12 persons worldwide, or some 500 million people, are living with chronic viral hepatitis. Viral hepatitis is among the top 10 infectious disease killers and the leading cause of liver cancer and cirrhosis. July 28th, 2011 is Worl
Unblinding Data Review Conference for Hepatitis B in Double-Blind Clinical Trial
Full Title: Unblinding Data Review Conference for NOVAFERON Hepatitis B in Random, Double-Blind, Positive Controlled and Multi-Center Clinical Research Held Genova Biotech has conducted NOVAFERON in the treatment of chronic hepatitis B in random, do
Full Title: Unblinding Data Review Conference for NOVAFERON Hepatitis B in Random, Double-Blind, Positive Controlled and Multi-Center Clinical Research Held Genova Biotech has conducted NOVAFERON in the treatment of chronic hepatitis B in random, do
Another Novel Bio-Protein Drug Obtains U.S. Patent
Following obtaining U.S. patents for the invention of the two novel protein drugs in 2009, Genova Biotech has received another U.S. invention patent for the important new protein drug on November 29,2011 issued by the U.S. Patent and Trademark Offic
Following obtaining U.S. patents for the invention of the two novel protein drugs in 2009, Genova Biotech has received another U.S. invention patent for the important new protein drug on November 29,2011 issued by the U.S. Patent and Trademark Offic
Genova CPC Branch Meeting¡ª¡°Expand in Organization Life¡±
To celebrate the 90th anniversary of founding the Communist Party of China (CPC), seven Genova Beijing members from the CPC Branch Committee have called a meeting on 1 July afternoon to advocate Expand in Organization Life. Seven non-party activists
To celebrate the 90th anniversary of founding the Communist Party of China (CPC), seven Genova Beijing members from the CPC Branch Committee have called a meeting on 1 July afternoon to advocate Expand in Organization Life. Seven non-party activists
¡°11th 5-year Plan¡±moving forward to ¡°12th 5-year Plan¡±
Recently Genova Biotech has received notification from the Chinese Biotechnology Development Center Ministry of Science and Technology that the assessment for NOVAFERON anti-cancer preclinical trial project has been passed in the 11th 5-year Plan an
Recently Genova Biotech has received notification from the Chinese Biotechnology Development Center Ministry of Science and Technology that the assessment for NOVAFERON anti-cancer preclinical trial project has been passed in the 11th 5-year Plan an
NOVAFERON ¨C Hepatitis B in Double-Blind Clinical Trial Successfully Completed
In June 2010 Genova Biotech commissioned the Central South University Xiangya Hospital and three other drug clinical trial centers for researches in Restructuring of Efficient anti-tumor anti-viral protein injection in the treatment of chronic Hepat
In June 2010 Genova Biotech commissioned the Central South University Xiangya Hospital and three other drug clinical trial centers for researches in Restructuring of Efficient anti-tumor anti-viral protein injection in the treatment of chronic Hepat